James D. Eskra

1.4k total citations
30 papers, 921 citations indexed

About

James D. Eskra is a scholar working on Pharmacology, Oncology and Biochemistry. According to data from OpenAlex, James D. Eskra has authored 30 papers receiving a total of 921 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pharmacology, 7 papers in Oncology and 6 papers in Biochemistry. Recurrent topics in James D. Eskra's work include Inflammatory mediators and NSAID effects (13 papers), Eicosanoids and Hypertension Pharmacology (6 papers) and Peptidase Inhibition and Analysis (4 papers). James D. Eskra is often cited by papers focused on Inflammatory mediators and NSAID effects (13 papers), Eicosanoids and Hypertension Pharmacology (6 papers) and Peptidase Inhibition and Analysis (4 papers). James D. Eskra collaborates with scholars based in United States, Japan and United Kingdom. James D. Eskra's co-authors include Thomas J. Carty, Ivan G. Otterness, Marcia L. Bliven, Anthony J. Milici, Michael J. Ernest, Francis J. Sweeney, Jean‐Pierre Pelletier, R. Griffiths, José R. Perez and Laurent Audoly and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

James D. Eskra

30 papers receiving 880 citations

Peers

James D. Eskra

PHARM

RHEUM

PHYSI

IMMUN

Charlotte Edenius Sweden

Carola Buccellati Italy

Yoshiharu Kikawa Japan

Kigen Kondo Japan

Makoto Katori Japan

Motofumi Yokoyama Japan

S L Hong United States

Arturo Mancini Canada

A Ichikawa Japan

S Higuchi Japan

Charlotte Edenius Sweden

James D. Eskra

276 ×0.8

PHARM

280 ×1.4

136 ×0.8

RHEUM

285 ×2.0

PHYSI

253 ×2.0

IMMUN

Citations per year, relative to James D. Eskra James D. Eskra (= 1×) peers Charlotte Edenius

Countries citing papers authored by James D. Eskra

Since Specialization

Citations

This map shows the geographic impact of James D. Eskra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James D. Eskra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James D. Eskra more than expected).

Fields of papers citing papers by James D. Eskra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James D. Eskra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James D. Eskra. The network helps show where James D. Eskra may publish in the future.

Co-authorship network of co-authors of James D. Eskra

This figure shows the co-authorship network connecting the top 25 collaborators of James D. Eskra. A scholar is included among the top collaborators of James D. Eskra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James D. Eskra. James D. Eskra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gustavson, Stephanie M., et al.. (2008). Non‐linear increase in GLP‐1 levels in response to DPP‐IV inhibition in healthy adult subjects. Diabetes Obesity and Metabolism. 10(6). 506–513. 22 indexed citations

Trebino, Catherine E., et al.. (2005). Redirection of Eicosanoid Metabolism in mPGES-1-deficient Macrophages. Journal of Biological Chemistry. 280(17). 16579–16585. 83 indexed citations

Reiter, Lawrence A., et al.. (2003). Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3. Bioorganic & Medicinal Chemistry Letters. 13(14). 2331–2336. 27 indexed citations

Sweeney, Francis J., James D. Eskra, Ralph H. Lambalot, et al.. (2003). Inhibition of IL-1β-dependent prostaglandin E2 release by antisense microsomal prostaglandin E synthase 1 oligonucleotides in A549 cells. Molecular and Cellular Endocrinology. 205(1-2). 151–157. 16 indexed citations

Wilner, Keith D., et al.. (2002). Celecoxib Does Not Affect the Antiplatelet Activity of Aspirin in Healthy Volunteers. The Journal of Clinical Pharmacology. 42(9). 1027–1030. 54 indexed citations

Otterness, Ivan G., Marcia L. Bliven, James D. Eskra, et al.. (2000). Cartilage damage after intraarticular exposure to collagenase 3. Osteoarthritis and Cartilage. 8(5). 366–373. 27 indexed citations

Otterness, Ivan G., et al.. (1998). Exercise protects against articular cartilage degeneration in the hamster. Arthritis & Rheumatism. 41(11). 2068–2076. 103 indexed citations

Carty, Thomas J., Francis J. Sweeney, R. Griffiths, et al.. (1997). Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models. Inflammation Research. 46(5). 168–179. 6 indexed citations

Bliven, Marcia L., James D. Eskra, & Ivan G. Otterness. (1997). Limitation of activity in an acute model of arthritis: Effect of drug treatment. Inflammation Research. 46(12). 491–495. 8 indexed citations

10.

Cheng, John B., J. W. Watson, Christopher J. Pazoles, et al.. (1997). The Phosphodiesterase Type 4 (PDE4) Inhibitor CP-80,633 Elevates Plasma Cyclic AMP Levels and Decreases Tumor Necrosis Factor-α (TNFα) Production in Mice: Effect of Adrenalectomy. Journal of Pharmacology and Experimental Therapeutics. 280(2). 621–626. 13 indexed citations

11.

Moore, Peter F., David Larson, Ivan G. Otterness, et al.. (1996). Tenidap, a structurally novel drug for the treatment of arthritis: Antiinflammatory and analgesic properties. Inflammation Research. 45(2). 54–61. 29 indexed citations

12.

Atkins, Paul C., Burton Zweiman, Bruce H. Littman, et al.. (1995). Products of arachidonic acid metabolism and the effects of cyclooxygenase inhibition on ongoing cutaneous allergic reactions in human beings. Journal of Allergy and Clinical Immunology. 95(3). 742–747. 14 indexed citations

13.

O’Connor, Brian, S. Uden, Thomas J. Carty, et al.. (1994). Inhibitory Effect of UK,74505, a Potent and Specific Oral Platelet Activating Factor (PAF) Receptor Antagonist, on Airway and Systemic Responses to Inhaled PAF in Humans. American Journal of Respiratory and Critical Care Medicine. 150(1). 35–40. 25 indexed citations

14.

Blackburn, Warren D., Louis W. Heck, Leland D. Loose, James D. Eskra, & Thomas J. Carty. (1991). Inhibition of 5‐lipoxygenase product formation and polymorphonuclear cell degranulation by tenidap sodium in patients with rheumatoid arthritis. Arthritis & Rheumatism. 34(2). 204–210. 49 indexed citations

15.

Otterness, Ivan G., et al.. (1991). Role of prostaglandins in the behavioral changes induced by murine interleukin 1α in the rat. Cytokine. 3(4). 333–338. 18 indexed citations

16.

Otterness, Ivan G., et al.. (1988). The pharmacologic regulation of interleukin-1 production: The role of prostaglandins. Cellular Immunology. 114(2). 385–397. 49 indexed citations

17.

Sweeney, Francis J., James D. Eskra, Michael J. Ernest, & Thomas J. Carty. (1987). Spectrophotometric monitoring of lipoxygenase and cyclooxygenase pathway activity using ionophore stimulated whole blood. Inflammation Research. 21(3-4). 393–396. 13 indexed citations

18.

Cheng, John B., et al.. (1987). Comparison of antigen and Ca++-ionophore-induced peptidoleukotriene release from guinea pig lung preparations using high-performance liquid chromatography.. Journal of Pharmacology and Experimental Therapeutics. 241(3). 786–792. 8 indexed citations

19.

Eskra, James D., et al.. (1986). Solid-phase extraction and high-performance liquid chromatography analysis of lipoxygenase pathway products. Analytical Biochemistry. 154(1). 332–337. 55 indexed citations

20.

Carty, Thomas J., James D. Eskra, Joseph G. Lombardino, & William W. Hoffman. (1980). Piroxicam, a potent inhibitor of prostaglandin production in cell culture. Structure-activity study. Prostaglandins. 19(1). 51–59. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact